-
Monopar Therapeutics' (MNPR) "Overweight" Rating Reaffirmed at Piper Sandler
来源: Buzz FX / 20 3月 2025 08:16:17 America/New_York
Monopar Therapeutics' (MNPR) "Overweight" Rating Reaffirmed at Piper Sandler Written by MarketBeat March 20, 2025 Share Link copied to clipboard. Remove Ads Monopar Therapeutics ( NASDAQ:MNPR - Get Free Report ) 's stock had its "overweight
Read more...